Worth reading
53Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Avoiding a definitive answer
How definitive the wording is.Announced details
Applicable field (uses covered by this announcement)
Understanding and treatment approaches for the onset and progression of myopia
Launch date27 April 2026 (date of announcement of the paper's publication)
Relationship between the counterparty and the company
Tsubota Laboratory Incorporated4890
Relationship with the Company
Joint Research
CounterpartyDepartment of Ophthalmology, Keio University School of Medicine
Location (as indicated in this announcement)
Shinjuku-ku, Tokyo (our company headquarters)
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
Source (materials cited by the company)
International academic journal iScience, DOI: 10.1016/j.isci.2026.115764
| Item | Details |
|---|---|
| Counterparty | Department of Ophthalmology, Keio University School of Medicine |
| Relationship with the Company | Joint Research |
| Launch date | 27 April 2026 (date of announcement of the paper's publication) |
| Applicable area | Understanding and treatment approaches for the onset and progression of myopia |
| Location | Shinjuku-ku, Tokyo (our company headquarters) |
| Source | International academic journal iScience, DOI: 10.1016/j.isci.2026.115764 |
Items this document does not state (12)
Names of Products / Services CoveredCounterparty overviewContract ValueOffering priceContract DateAward/certification nameAwarding / certifying bodyRegistration number and expiry dateLocation scaleQuantitative EffectsUsage historyImpact on Business Performance
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To investigate the effects of choroidal macrophage polarization on the progression of myopia and demonstrate the potential for new approaches to understanding and treating myopia.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.